UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share CATB The Nasdaq Stock Market LLC FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...

Edasalonexent Clinical Development - Edasalonexent is a late-stage therapeutic candidate for Duchenne Muscular Dystrophy (DMD), designed to limit muscle degeneration, promote muscle regeneration, and reduce inflammation and fibrosis[7, 72] - The Phase 3 PolarisDMD trial enrolled 131 boys ages 4 to 7, with top-line results expected in Q4 2020[26, 30] - In the Phase 2 MoveDMD trial and open-label extension, all assessments of function stabilized on Edasalonexent compared to the off-treatment control period[48] - Edasalonexent has been well-tolerated in more than 150 years of cumulative patient exposure[25, 72] - A trial in non-ambulatory DMD patients is expected to initiate in 2021 with support from Duchenne UK, who granted over $600,000 in funding[71] Market Opportunity and Commercial Strategy - DMD affects 1 in 3,500-5,000 males worldwide, with a median life expectancy of approximately 30 years[8, 82, 83] - Approximately 40% of patients are diagnosed by age 4[82, 85] - The company has developed strong relationships with global Duchenne patient advocacy organizations[86] - Most US Duchenne patients have access to expert care and treatment through concentrated treatment centers[92, 94] - Edasalonexent aims to be a foundational therapy for all patients affected by Duchenne, regardless of dystrophin mutation, and can be used as mono- or potential combo-therapy[20, 99]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share CATB The Nasdaq Stock Market LLC FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37467 Catabasis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3687168 (State or Other ...

Catabasis Pharmaceuticals Inc. (CATB) Q4 2019 Earnings Conference Call March 10, 2020 8:30 AM ET Company Participants Andrea Matthews - Vice President, Corporate Affairs Jill Milne - Chief Executive Officer Joanne Donovan - Chief Medical Officer Andrew Komjathy - Chief Commercial Officer Andy Nichols - Chief Scientific Officer Noah Clauser - Vice President, Finance Conference Call Participants Liana Moussatos - Wedbush Securities Hartaj Singh - Oppenheimer Operator Ladies and gentlemen, thank you for standi ...